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Abstract 14-3-3 Proteins are thought to function as adapters in
signaling complexes [1,2], thereby participating in cellular
processes including vesicle trafficking and exocytosis [3,4]. To
delineate further the function of 14-3-3 proteins during vesicle
trafficking, we generated dominant-negative alleles of the two
14-3-3 homologues, Bmh1p and Bmh2p, in budding yeast and
analyzed their phenotype in respect to exocytosis. Cells over-
expressing the carboxy-terminal region of Bmh2p failed to
polarize vesicular transport although bulk exocytosis remained
unaffected and showed a disrupted actin cytoskeleton. Our data
suggest that 14-3-3 proteins may act primarily on the actin
cytoskeleton to regulate vesicle targeting.
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1. Introduction
14-3-3 Proteins represent a family of ubiquitously expressed
dimeric proteins of approximately 30 kDa. Homologues of
this family are present in all eukaryotic cells and several iso-
forms are known [1,5]. These proteins are implicated in plei-
otropic functions ranging from activation of tyrosine and
tryptophan hydroxylases [6], regulation of protein kinase C
[7^10], cell cycle regulation [11] to exocytosis [3,4]. In addi-
tion, they were identi¢ed as binding partners for many signal-
ing proteins including Raf 1 kinase [11^14], Bcr-Abl [15] and
PI3 kinase [16]. It is believed that the variety of binding part-
ners and the participation in numerous cellular processes is
due to their role as adapter proteins, which are involved in the
spatial organization of signaling complexes [1,2].
14-3-3 Proteins have been shown to modulate vesicle traf-
¢cking and exocytosis in di¡erent experimental systems,
although little is known about the signaling cascades involved
here. In permeabilized adrenal chroma⁄n cells, 14-3-3 pro-
teins were found to reconstitute catecholamine secretion
[3,17], which was accompanied by a rapid and transient dis-
assembly of the actin network [18]. This is likely to facilitate
the movement of secretory granules towards the plasma mem-
brane prior to granule docking and fusion [18]. In Drosophila,
a 14-3-3 zeta homologue termed LEONARDO was discovered
in a screen for learning and memory mutants [4,19]. Muta-
tions in LEONARDO caused a defect in synaptic transmission
which became more severe upon high frequency stimulation,
when more vesicle turn-over in the synapse was required [20].
In a more general aspect of vesicle transport, two 14-3-3 ho-
mologues in the yeast Saccharomyces cerevisiae, Bmh1p and
Bmh2p, were identi¢ed in a screen for gene products whose
overexpression compensates an endocytosis defect caused by
clathrin heavy chain deletion [21].
In order to further delineate the function of 14-3-3 protein
in vesicle transport, we turned to the budding yeast S. cere-
visiae, a well-established model system for polarized vesicle
tra⁄cking with the additional advantage that it possesses
only two 14-3-3 genes, BMH1 and BMH2, in contrast to
higher eukaryotes. Deletion of single BMH genes does not
a¡ect cell viability [21,22], but double deletions of BMH1
and BMH2 are generally lethal [21,22].
The yeast 14-3-3 Bmh1p and Bmh2p proteins share 92%
amino acid identity with each other and approximately 60%
with 14-3-3 orthologues from higher eukaryotes. Here, we
exploited this high extent of sequence conservation between
yeast and mammalian isoforms to design a dominant-negative
approach in yeast by overexpressing individual domains of the
yeast 14-3-3 proteins. A phenotypic analysis of yeast cells
overexpressing the carboxy-terminal domain of Bmh2p re-
vealed that these cells are increased in cell size, they no longer
polarize post-Golgi secretory transport and their actin cyto-
skeleton is disrupted. We conclude that the yeast 14-3-3 pro-
teins are involved in pathways that control the organization of
the actin cytoskeleton and thereby modulate vesicle targeting
and cell polarity.
2. Materials and methods
2.1. Yeast genetic techniques
Cultures were grown in rich medium (YP) containing 1% (w/v)
Bacto yeast extract and 2% (w/v) Bacto peptone (Difco) or in syn-
thetic medium containing 0.7% (w/v) yeast nitrogen base without ami-
no acids (Difco). Synthetic medium was supplemented with nutrients
if necessary as described [25]. Glucose was generally used as a carbon
source (2% (w/v) ¢nal concentration) except in experiments requiring
expression from the GAL1 promoter. In this case, cells were pre-
grown in 2% (w/v) ra⁄nose to the early log phase and then, expres-
sion from the GAL1 promoter was turned on by addition of 2% (w/v)
galactose to the medium. Yeast transformations were performed with
the lithium-acetate method [24] and transformants were selected on
synthetic media supplemented with nutrients as required.
2.2. Generation of 14-3-3 domains for expression in yeast
Yeast 14-3-3 (BMH1 and BMH2) fragments (see Fig. 1) were gen-
erated by PCR with BamHI (at the 5P end) and HindIII or BamHI (at
the 3P end) overhangs. For internal fragments, start and stop codons
were added. The PCR fragments were subcloned into a yeast integrat-
ing vector containing a GAL1 promoter and ADH terminator with
URA3 as the auxotrophic marker (kindly provided by Peter Novick).
All inserts were veri¢ed by DNA sequencing. The resulting plasmids
were linearized with StuI to allow for homologous recombination and
integration at the site of the auxotrophic marker URA3.
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2.3. Immuno£uorescence
Immuno£uorescence was carried out as described before [26] with
modi¢cations [27]. Yeasts were grown at 25‡C to an OD600 of approx-
imately 0.2 in YP containing 2% (v/v) glycerol. Overexpression of
proteins from the GAL1 promoter was induced by addition of galac-
tose (2% (w/v) ¢nal concentration) directly to the medium. Cells were
grown for a further 10 h before ¢xation. Temperature-sensitive mu-
tants were grown in YP containing 2% (w/v) glucose at 25‡C to the
mid-log phase and then shifted for 1 h to 37‡C before harvesting and
¢xing. Anti-Sec4p antibody (provided by P. Novick) was used at
1/1000 dilution for 1 h at room temperature. Secondary antibody
incubation was for 30 min at room temperature with Cy3-conjugated
goat anti-rabbit antibodies at 1/500 dilutions. Cells were observed
with a Zeiss Axiophot using a 100U objective unless otherwise stated
and photographed using TMAX 400 ¢lm (Kodak).
2.4. Actin and 4P,6P-diamidino-2,4-phenylindole (DAPI) staining
Actin and DAPI stainings were essentially performed as described
previously [28]. Cells were grown as before for 10 h to induce expres-
sion from the GAL1 promoter. Cells were observed with a Zeiss Ax-
iophot using a 100U objective. Pictures were taken and assembled as
described above.
2.5. Invertase secretion
Invertase secretion was performed as described [29] with some mod-
i¢cations. All yeast strains were pre-grown in galactose as above to
the mid-log phase. To measure invertase secretion from cells grown in
galactose, the expression of invertase had to be repressed before the
start of the experiment by shifting the cells to 2% (w/v) glucose for 1 h.
This treatment did not a¡ect the morphology of the cells. Further
processing of the cells for determining invertase activity was as de-
scribed [29].
Liberated glucose generated by invertase activity was measured in
microtiter plates using a colorimetric assay [30]. Fifteen Wl of each
sample was incubated for 30 min at 37‡C with 100 Wl assay mix II
(500 U glucose oxidase, 2.5 Wg/ml peroxidase, 0.15 Wg/ml o-dianisi-
dine, 20 WM N-ethyl maleimide in phosphate-bu¡ered saline). Then,
the reaction was terminated by addition of 100 Wl 6 N HCl. The
absorbance of the samples was read at A540 in an enzyme-linked
immunosorbent assay reader and the percentage of invertase secreted
from the total cellular invertase content during the 1 h time interval
was calculated. The total cellular invertase contents were normalized
to 100%. The experiment was performed three times and samples were
analyzed in duplicates each time.
3. Results
Previous data on mammalian 14-3-3 proteins had shown
that the amino-terminal region is required for homo- and
hetero-dimerization, while the carboxy-termini may determine
their speci¢city for binding to distinct partner proteins [31^
33]. To identify regions in the yeast 14-3-3 homologues,
Bmh1p and Bmh2p, that are functionally important in vivo,
we generated fragments encompassing various domains of
Bmh1p and Bmh2p. These fragments were then conditionally
overexpressed in yeast in an attempt to competitively interfere
with the function of the endogenous Bmh proteins.
The following fragments depicted in Fig. 1A were tested: (i)
the amino-termini (NT/BMH1 and NT/BMH2), i.e. regions
corresponding to the dimerization interface in the mammalian
14-3-3 isoforms, (ii) fragments of the extreme carboxy-termi-
nal domains (CT/BMH1 and CT/BMH2), which are analo-
gous to the putative e¡ector protein binding site in the mam-
malian 14-3-3 proteins, and (iii) a fragment of the putative
partner protein binding groove that is identical in the two
yeast 14-3-3 homologues, termed H56/BMH1/2. E¡ects of
the induced Bmh1p and Bmh2p domains were then scored
by comparing the growth of the stable integrants on media
containing galactose where expression from the GAL1 pro-
moter is induced to growth on media containing glucose,
where the GAL1 promoter is repressed.
Fig. 1B shows that some of the transformants grew on
glucose and not on galactose, as predicted for dominant-neg-
ative alleles. This pattern of growth was temperature-inde-
pendent since the same pattern was observed at 25, 30 and
37‡C (data not shown). In this overexpression assay, the ami-
no- and carboxy-terminal domains of Bmh2p, but not of
Bmh1p, were dominant-negative for growth, whereas the
shared domain H56/BMH1/2 was not. Interestingly, the dom-
inant-negative regions of Bmh2p correspond to those regions
of mammalian 14-3-3 orthologues that are supposed to be
involved in dimer formation (NT/BMH2) or e¡ector protein
binding (CT/BMH2) [31^33].
To understand the function of the yeast 14-3-3 proteins, we
analyzed the phenotypes of cells expressing dominant-negative
alleles of Bmh2p, NT/BMH2 and CT/BMH2. Light micros-
copy showed that the overall sizes of these cells were approx-
imately 40^50% larger than wild-type cells (data not shown).
Fig. 1. E¡ects of overexpression of Bmh1p and Bmh2p fragments
on cell growth. (A) Schematic representation of the deletion con-
structs generated. The upper panel indicates the sizes of the full-
length open reading frames for Bmh1p and Bmh2p. The lower panel
depicts the various deletion mutants generated. NT/BMH1 and NT/
BMH2: amino-terminus of Bmh1p and Bmh2p, respectively. CT/
BMH1 and CT/BMH2: carboxy-terminus of Bmh1p and Bmh2p,
respectively. H56/BMH1/2: domain common to both Bmh1p and
Bmh2p. Numbers next to the cartoons indicate amino acid numbers.
(B) Cell growth after overexpression of deletion mutants of Bmh1p
and Bmh2p. Three independent clones containing deletion constructs
of either Bmh1p or Bmh2p under the control of the inducible
GAL1 promoter were grown at 25‡C on rich medium in the pres-
ence of glucose (YPD) or galactose (YPGal). In the presence of glu-
cose, the expression from the GAL1 promoter was repressed, while
in the presence of galactose, expression from the GAL1 promoter
was induced. Yeast strains abbreviated according to their respective
integrated construct are depicted on the right. Note that only strains
carrying alleles of NT/BMH2 and CT/BMH2 act dominant-negative
upon growth on galactose.
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No apparent phenotypic di¡erences were seen between cells
expressing the amino- or the carboxy-terminal regions of
Bmh2p. Therefore, all subsequent experiments were per-
formed only with cells overexpressing the carboxy-terminus
of Bmh2p, CT/BMH2.
As 14-3-3 proteins have been implicated in the modulation
of exocytosis in both mammalian cells [3] and Drosophila [19],
we examined whether the extent of secretion was altered in
yeast expressing CT/BMH2. To this end, we measured con-
stitutive secretion of invertase from post-Golgi vesicles into
the periplasmic space by a colorimetric assay [29,30]. Fig. 2
shows that the percentage of invertase secretion in cells with
dominant-negative 14-3-3 alleles was only marginally reduced.
As a control, invertase secretion from a temperature-sensitive
secretion mutant, sec4-8, was measured in parallel. Here, in-
vertase secretion was reduced by approximately 90% when the
cells were shifted to the restrictive temperature (Fig. 2) [29].
We conclude from these data that 14-3-3 proteins do not
participate in the ¢nal stages of vesicle docking and fusion.
Measuring invertase secretion only mirrors bulk exocytosis
and potential defects in vesicle targeting are not detected. In-
deed, invertase secretion was not drastically reduced in the
two cytoskeleton mutants, act1-3 and myo2-66, which were
also analyzed here for their ability to secrete invertase at the
permissive and restrictive temperatures (Fig. 2). These mu-
tants are known to exhibit vesicle tra⁄cking defects [34]. In
both act1-3 and myo2-66 strains, vesicles are no longer tar-
geted to the bud tip and the neck region [26,35]. As over-
expression of CT/BMH2 causes a morphology similar to
that of act1-3 and myo2-66 mutants [34,35], we considered
that the polarized transport of vesicles to the bud tip or the
neck region may be defective after CT/BMH2 overexpression.
Fig. 2. Invertase secretion is not altered upon overexpression of the
carboxy-terminus of Bmh2p. Invertase secretion from wild-type pa-
rental cells (3CT/BMH2), cells conditionally overexpressing the car-
boxy-terminus of Bmh2p (+CT/BMH2) and cells with temperature-
sensitive mutations in Sec4p (sec4-8), actin (act1-3) or the unconven-
tional myosin Myo2p (myo2-66) at the permissive (25‡C, ‘25’) or the
restrictive (37‡C, ‘37’) temperature were measured as described
under Section 2. The amount of secretion during a 1 h time interval
was calculated. The experiment was performed in duplicates three
times. The error bars indicate the S.E.M. (n = 6).
Fig. 3. The polarized localization of Sec4p immuno£uorescence is lost in cells overexpressing the carboxy-terminus of Bmh2p. Wild-type cells
(A), cells conditionally overexpressing the carboxy-terminus of Bmh2p (B) and cells with a temperature-sensitive mutation of Sec4p, sec4-8,
grown at 25‡C (C) or shifted to 37‡C for 1 h (D) were all grown in galactose. Cells were then ¢xed in formaldehyde, the cell wall was removed
and stained with a polyclonal antibody recognizing Sec4p to indicate active sites of growth (indicated by arrows). Note the lack of a localized
£uorescent signal for Sec4p in B. Scale bar: 1 Wm.
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Potential vesicle targeting defects were therefore analyzed by
indirect immuno£uorescence with a vesicle marker, the rab-
like GTPase Sec4p [36].
Sec4p staining in wild-type cells marks the sites of exocy-
tosis according to the respective stage of the cell cycle at the
bud tip or the neck region [36] and is thus a reliable indicator
of polarized secretion. Cells harboring the CT/BMH2 allele
(Fig. 3B) and the parental cells (Fig. 3A) were grown in ga-
lactose before indirect immuno£uorescence for Sec4p was per-
formed. The majority of cells overexpressing CT/BMH2 failed
to show localized Sec4p staining at the bud tip or the neck
region (Fig. 3B). Localized Sec4p staining was only visible in
18.8% of cells (n = 841) overexpressing CT/BMH2, whereas
79.7% of the parental cells (n = 675) showed a correctly local-
ized Sec4p £uorescence signal at the bud tip or the neck.
Furthermore, Sec4p £uorescence was prominent throughout
the entire cell after CT/BMH2 overexpression, consistent
with an even distribution of vesicles throughout the cells.
Control experiments in which either the secondary antibody
was omitted (data not shown) or a sec4-8 temperature-sensi-
tive mutant was used (Fig. 3C,D) revealed a marked reduction
in the £uorescence signals (Fig. 3D), consistent with previ-
ously reported observations [36,37]. We therefore conclude
that overexpression of CT/BMH2 causes a loss of localized
Sec4p staining but not a complete loss of the Sec4p £uores-
cence signal. This loss of a localized £uorescence signal could
not be attributed to a decrease in the levels of Sec4p expres-
sion since lysates of parental cells and cells overexpressing CT/
BMH2 showed equal levels of Sec4p as judged by Western
blot analysis (data not shown). This suggests that Sec4p-con-
taining vesicles were randomly distributed upon CT/BMH2
overexpression. Our data are thus indicative of a vesicle tar-
geting defect.
Given the previous indication of a potential role of 14-3-3
proteins on the actin cytoskeleton [18], we next analyzed the
organization of the actin cytoskeleton in cells overexpressing
CT/BMH2 (Fig. 4A). Staining of ¢lamentous actin with
TRITC-phalloidin in cells expressing the dominant-negative
allele showed the occurrence of large actin clusters that
frequently appeared in the neck region (Fig. 4B). Further-
more, actin patches, if existent, were distributed throughout
the cell, while actin cables were no longer visible. These data
demonstrate that overexpression of CT/BMH2 causes defects
in the organization of the actin cytoskeleton. As ¢lamentous
actin in yeast may serve as tracks for vesicle transport from
the Golgi to the plasma membrane, the observed changes in
the actin cytoskeleton resulting from CT/BMH2 overexpres-
sion may explain why these cells display vesicle targeting
defects.
4. Discussion
Here, we have analyzed the e¡ect of dominant-negative
alleles of 14-3-3 proteins on vesicle tra⁄cking from the
trans-Golgi network to the plasma membrane and on the
actin organization in a highly polarized organism, the budding
yeast S. cerevisiae. Our data show that domains in the amino-
and carboxy-terminal regions of one 14-3-3 homologue,
Bmh2p, but not of Bmh1p, become dominant-negative for
growth upon overexpression. Analysis of the phenotype of
cells overexpressing the carboxy-terminus of Bmh2p revealed
that bulk invertase secretion remained unaltered, whereas the
polarized localization of Sec4p, characteristic for vesicle trans-
port to sites of active growth, was lost. In addition, the or-
ganization of the actin cytoskeleton was severely altered.
These data indicate that at least one 14-3-3 yeast homologue
is involved in pathways controlling actin organization and
thereby in the targeting of post-Golgi vesicles to speci¢c sites
at the plasma membrane.
Our data demonstrate an in vivo function for the amino-
and carboxy-termini of Bmh2p, which after overexpression
cause an inhibition of cell growth. As the amino-terminus of
Fig. 4. The actin cytoskeleton is disrupted upon overexpression of CT/BMH2. Wild-type cells (wt) and cells overexpressing CT/BMH2 were
pre-grown in rich medium containing glycerol and then induced in galactose-containing medium for 10 h. Cells were then ¢xed in formaldehyde
and stained with TRITC-phalloidin to visualize ¢lamentous actin (column labelled as F-Actin) and co-stained with DAPI (column labelled as
DNA) to visualize nuclei. Arrow heads indicate actin patches that are localized in wild-type cells or became delocalized upon overexpression
of CT/BMH2. Small arrows indicate actin ¢laments present in wild-type cells. The asterisks show the localization of actin clusters. Scale bar:
1 Wm.
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mammalian 14-3-3 proteins is known to be required for the
formation of dimers [38^41] and the fragments used in this
study are likely to encompass these dimerization domain as
judged by amino acid homology (65% amino acid identity
between Bmh2p and rat zeta in this region), the growth in-
hibition occurring upon NT/BMH2 overexpression provides a
¢rst indication that dimerization of 14-3-3 proteins is of func-
tional importance in vivo.
The carboxy-termini of Bmh1p and Bmh2p may be in-
volved in binding to downstream partner proteins as sug-
gested for mammalian 14-3-3 isoforms [31^33]. Growth inhib-
ition upon overexpression of CT/BMH2 is therefore indicative
of a blockade of the downstream signaling pathway required
for cell function. However, we cannot rule out that Bmh1p
also functions in a similar pathway as we were not able to
judge by Western blot analysis the relative expression levels of
the overexpressed Bmh1p and Bmh2p fragments.
In CT/BMH2 overexpressing yeast cells, we did not see a
defect in bulk invertase secretion but found a loss of targeted
vesicle transport to the plasma membrane. This may be attrib-
uted to a breakdown of the actin cytoskeleton as indicated by
the presence of actin clusters and the occurrence of bundles of
micro¢laments. Numerous reports support the idea that the
actin cytoskeleton provides a track for polarized vesicle trans-
port in yeast [26,43,44]. Temperature-sensitive mutations of
actin are defective in polarized transport when grown at the
restrictive temperature [34] and disruption of ¢lamentous ac-
tin by the toxin latrunculin A results in a loss of vesicle polar-
ization as revealed by a loss of Sec4p staining at the bud tip
[26]. Depending on the cell type and the predominant role of
the actin cytoskeleton, disruption of 14-3-3 function may pro-
duce di¡erent e¡ects on the secretory process. In polarized
cells such as yeast, the major role of the actin cytoskeleton
in secretion may be to direct vesicles to sites of active growth
[26,44]. Consequently, localized secretion directly depends on
14-3-3 function. In contrast, in chroma⁄n cells, where a dense
cortical network underlies the plasma membrane and where
secretory granules are largely stored in the cytoplasm, the
transport of these granules to the plasma membrane depends
on the removal of this cortical actin barrier [42,45,46]. Hence,
proteins removing this barrier, like actin severing proteins and
14-3-3 proteins, will facilitate secretion in this type of cells
[18,47,48].
It is tempting to speculate that modulation of the actin
cytoskeleton by 14-3-3 proteins may play a general role in
the establishment of cell polarity including cellular morpho-
genesis. One potential pathway through which 14-3-3 proteins
may conceivably act to modulate the actin organization in
yeast is the MAP kinase pathway. Bmh1p and Bmh2p have
recently been shown to bind to Ste20p, one component of
the yeast MAP kinase pathway involved in morphogenesis
during pheromone response signaling [23]. It remains to be
shown whether this or other pathways mediate 14-3-3 protein
regulation of the actin cytoskeleton and of secretory proc-
esses.
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